Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.
EP. 1: Best Practices for Molecular Testing in Early-Stage Breast Cancer
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
EP. 2: How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
EP. 3: Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
EP. 4: How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
EP. 5: HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
EP. 6: Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.
EP. 7: Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
EP. 8: Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
EP. 9: HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
EP. 10: Other Treatment Modalities for HR+ Metastatic Breast Cancer
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
EP. 11: Evolution in the Field of HR+ Breast Cancer Management
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma
Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor
Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer
Revisit Every OncLive On Air Episode From January 2025